

Contents

Series Editors Preface *xxi*

Preface *xxiii*

1	Aspects for Developing and Processing Solid Forms	1
	<i>Michael Gruss</i>	
1.1	Aspects for Developing and Processing Solid Forms	1
1.1.1	Introduction	1
1.1.2	Education and Personal Background	1
1.1.3	Societal Impact – Fishing in Foreign Waters	4
1.1.3.1	Motivation	4
1.1.3.2	The Personal Dimension	5
1.1.3.3	Beyond the Impact on Individuals	6
1.1.3.4	Understanding the Market – Not an Easy Task	7
1.1.3.5	Benefits of an Interdisciplinary Mindset	9
1.1.4	The Basis for Mutual Understanding	9
1.1.5	Crystallization is a Separation, Not a Separated Process	11
1.1.6	Some Early Information About Solid-state Properties	13
1.1.7	Digitalization (Not Only) in the Laboratory	13
1.1.7.1	Prerequisites – Technology and People	13
1.1.7.2	Connect Data and the Right Information from Synthesis and Analysis	15
1.1.7.3	Contributions and Choices	17
1.1.7.4	Application of Digitalization	18
1.1.7.5	Fully Digitalized Infrastructure	20
1.1.8	Basic Terms and Concepts in the World of Solid State	21
1.1.8.1	Crystalline and Amorphous	21
1.1.8.2	Crystallization and Precipitation	23
1.1.8.3	Understanding the Phase Diagram – Analytical Characterization of the Solid–Liquid and Solid–Solid Systems	23
1.1.8.4	Polymorphism	24
1.1.8.5	Multi-component Compounds – Salt, Cocrystal, Solvate, and Hydrate	25
1.1.8.6	Solvates, Hydrates, Non-solvated Forms, or Ansolvates	26

1.1.8.7	Dispersed Primary Particles, Aggregates, and Agglomerates	29
1.1.8.8	Particle Size and Particle Size Distribution (PSD)	29
1.1.9	Investigating and Understanding the Polymorphic Landscape	29
1.1.10	Performing the Crystallization	31
1.1.11	Objectives for the Optimization of Crystallization Processes and Solid-State Properties	32
1.1.12	Implementation of In Silico and Simulation Techniques	32
1.1.13	Saving the Investment – Addressing Intellectual Property Rights	35
1.1.14	Concluding Remarks	36
	List of Abbreviations	37
	References	38
2	Determination of Current Knowledge	45
	<i>Andriy Kuzmov and Ronak Savla</i>	
2.1	Why Is it Important to Search for Relevant Information Before Starting a Solid-State Project?	45
2.2	Where to Begin a Literature Search for a Solid-State Project?	47
2.2.1	Literature Search	48
2.2.1.1	Focusing Your Literature Search	49
2.2.2	Staying on Top of the Latest Publications	51
2.3	Patent Search	51
2.3.1	Types of Patent Reports	52
2.3.2	Understanding the Elements of Patents	53
2.3.3	Patent Classification	54
2.3.4	Patent Databases	56
2.3.4.1	Free Patent Databases	57
2.4	Other Useful Resources for Solid-State Projects	61
2.4.1	Cambridge Structural Database	61
2.4.2	Crystallography Open Database	62
	List of Abbreviations	62
	References	63
3	Systematic Screening and Investigation of Solid-State Landscapes	67
	<i>Ulrike Werthmann</i>	
3.1	Introduction	67
3.2	General Aspects of Solid-State Investigations in Early Drug Discovery Phase	68
3.3	Transition Phase from Late Stage Research to Early Stage Development	69
3.4	Solid-State Characteristics in Preclinical Formulations	70
3.5	API-crystallization Strategy in Candidate Profiling Phase	73
3.6	Selection Criteria of a Suitable Solid Form	77
3.7	Knowledge Management	79
3.8	Control of Solid Form Properties in Development	79

3.9	Exploratory Crystallization Experiments	80
	List of Abbreviations	87
	References	88
4.1	Solid-State Characterization Techniques: Microscopy	91
	<i>Luis Almeida e Sousa and Constança Cacula</i>	
4.1.1	Microscopy	91
4.1.1.1	Optical Microscopy	91
4.1.1.1.1	Bright-Field Microscopy	92
4.1.1.1.2	Dark-Field Microscopy	93
4.1.1.1.3	Polarized Light Microscopy	93
4.1.1.1.4	Other Optical Microscopy Variants	95
4.1.1.2	Electron Microscopy	96
4.1.1.2.1	Scanning Electron Microscopy	96
4.1.1.2.2	Transmission Electron Microscopy	100
4.1.1.3	Atomic Force Microscopy	101
4.1.1.4	Microscopy in Regulatory Documents	103
	List of Abbreviations	103
	References	104
4.2	Standards and Trends in Analytical Characterization – X-ray Diffraction (XRD)	107
	<i>Clemens Kühn</i>	
4.2.1	X-ray Diffraction	107
4.2.1.1	Introduction	107
4.2.1.2	Measurement Principles	108
4.2.1.2.1	The Crystal Lattice	108
4.2.1.2.2	The Space Group Symmetry	108
4.2.1.2.3	What Determines a Diffraction Peak	109
4.2.1.2.4	X-ray Scattering Technics	110
4.2.2	Technics	110
4.2.2.1	Single Crystal X-ray Diffraction	110
4.2.2.2	Powder X-ray Diffraction	111
4.2.2.2.1	Alternative Methods for Structure Determination	111
4.2.3	Instrumentation	112
4.2.3.1	X-ray Sources	112
4.2.3.2	Diffractometer Geometries	113
4.2.3.2.1	Reflection Geometry	113
4.2.3.2.2	Transmission Geometry	114
4.2.3.2.3	Benchttop Diffractometers	115
4.2.3.3	Detectors	115
4.2.3.4	Peak Asymmetry	115
4.2.3.5	Reproducibility of Diffraction Patterns: The Texture Effect (Preferred Orientation)	116
4.2.3.6	Databases of Known Diffraction Patterns	118

4.2.4	Measurement	118
4.2.4.1	Instrument Calibration	118
4.2.4.2	Sample Preparation	119
4.2.5	Data Evaluation	119
4.2.5.1	Qualitative Phase Analysis	119
4.2.5.1.1	Phase Identification or Identity Check	120
4.2.5.1.2	Amorphous Content	121
4.2.5.2	Quantification	122
4.2.5.2.1	Based on Calibration Curve	123
4.2.5.2.2	Based on Internal Standard Addition	123
4.2.5.2.3	Based on Rietveld Refinement	123
4.2.5.3	Advanced Phase Analysis	124
	List of Abbreviations	125
	References	125
	Further Reading	127
 4.3	Standards and Trends in Solid-State Characterization Techniques – Thermal Analysis	 129
	<i>Juergen Thun and Nikolaus Martin</i>	
4.3.1	Introduction	129
4.3.2	Thermal Analysis in Drug Development	130
4.3.2.1	Solid form Landscape	130
4.3.2.2	Compatibility Studies	130
4.3.2.3	Other Applications	130
4.3.3	Methods	131
4.3.3.1	Differential Scanning Calorimetry	131
4.3.3.1.1	Techniques	131
4.3.3.1.2	Sample Preparation and Measuring Parameters	131
4.3.3.1.3	Evaluation	132
4.3.3.1.4	Special Applications	134
4.3.3.1.5	Detection Limits	134
4.3.3.2	Thermogravimetric Analysis	134
4.3.3.2.1	Technique	134
4.3.3.2.2	Sample Preparation and Measuring Parameters	135
4.3.3.2.3	Evaluation	135
4.3.3.2.4	Special Applications	136
4.3.4	Case Studies	136
4.3.4.1	Understanding Polymorphic Transitions	136
4.3.4.2	The Power of Ultra-fast Heating Rates	139
4.3.4.3	Understanding Amorphous Phases	141
4.3.4.4	Identification of Solvate Structures	142
4.3.5	Quality and Regulatory Aspects	144
4.3.6	Outlook	145
	Acknowledgments	146

List of Abbreviations 146

Notes 146

References 146

4.4 Standards and Trends in Solid-State Characterization

Techniques: Infrared (IR) Spectroscopy 151

Dagmar Lischke

4.4.1 Infrared (IR) Spectroscopy 151

4.4.1.1 Introduction 151

4.4.1.2 IR Spectroscopy as Identity Method for Drug Substances 152

4.4.1.2.1 Transmission Mode 152

4.4.1.2.2 Attenuated Total Reflectance (ATR) 152

4.4.1.2.3 Sample preparation 153

4.4.1.2.4 Analysis and Reporting 153

4.4.1.2.5 Examples and Limitations 154

4.4.1.2.6 Method Validation of IR Spectroscopy Identification and Quantification

Methods 155

4.4.1.3 Application of IR Microscopy-Imaging Methods in Drug Development 156

4.4.1.3.1 Spatial Resolution 156

4.4.1.3.2 Measurement Setups 157

4.4.1.3.3 Case Studies 158

4.4.1.4 Conclusion 162

List of Abbreviations 162

References 163

4.5 Transmission Raman Spectroscopy – Implementation in Pharmaceutical Quality Control 165

Meike Römer

4.5.1 Raman Spectroscopy – From Research to Broad Applications in Industry 165

4.5.1.1 Objective 165

4.5.1.1.1 History 165

4.5.1.1.2 Introduction 165

4.5.1.1.3 The Raman Effect 166

4.5.2 Analytical use of Raman Spectroscopy for Pharmaceutical Purposes 167

4.5.2.1 Transmission Raman Spectroscopy (TRS) 167

4.5.2.1.1 Principles of Transmission Raman Spectroscopy 168

4.5.2.1.2 A Practical Guide to a Successful Business Case 171

4.5.3 Transmission Raman Spectroscopy – Another Practical Guide 173

4.5.3.1 Evaluation Phase 174

4.5.3.1.1 Prefeasibility Evaluation 174

4.5.3.1.2 Feasibility of a Product 176

4.5.3.2 Transmission Raman Method Development 177

4.5.3.2.1	Transmission Raman Spectroscopic Method Development	177
4.5.3.2.2	Risk Analysis	179
4.5.3.2.3	Transmission Raman Model Development, Calibration, and Validation	180
4.5.4	Regulatory Assessment and Guidelines	180
	List of Abbreviations	181
	References	182
4.6	Solid-state Characterization Techniques: Particle Size	185
	<i>Maria Paisana and Constança Cacela</i>	
4.6.1	Introduction	185
4.6.2	Analytical Methodologies Used to Measure Particle Size	187
4.6.2.1	Sedimentation	187
4.6.2.2	Electrozone Sensing	187
4.6.2.3	Sieving	188
4.6.2.4	Microscopy	188
4.6.2.5	Dynamic Light Scattering	188
4.6.2.6	Laser Diffraction	189
4.6.3	Method Development for Precise Particle-size Measurements by Laser Diffraction	189
4.6.3.1	Instrumentation and Measurement	189
4.6.3.2	Selection of an Appropriate Optical Model	190
4.6.3.3	Sample Dispersion	191
4.6.3.3.1	Wet Dispersion	192
4.6.3.3.2	Dry Dispersion	194
4.6.3.4	Sample Representativeness and Obscuration	195
4.6.3.5	Readiness for Method Validation	196
4.6.4	Unexpected Results and Troubleshooting in Laser Diffraction Measurement	197
4.6.4.1	Inconsistent Disconnected Peaks	197
4.6.4.2	Repeatable Artifact Peaks	199
	List of Abbreviations	199
	References	200
4.7	Micro Computational Tomography	203
	<i>Susana Campos and Constança Cacela</i>	
4.7.1	Tomography Imaging Techniques	203
4.7.2	Micro X-ray Computed Tomography Scan	203
4.7.2.1	The Use of CT in the Pharmaceutical Industry	204
4.7.2.1.1	μCT Applied to Density Distribution and Porous Characterization	205
4.7.2.1.2	μCT Applied for Characterization of Structural Features: Size, Shape, and Dimensions and Interfaces	207
4.7.2.1.3	μCT Applied to Coating Characterization	207
4.7.2.1.4	μCT Applied to Performance Evaluation	209

4.7.2.1.5	Foreign Matter Detection by μ CT	210
	List of Abbreviations	211
	Notes	211
	References	211
4.8	In Situ Methods for Monitoring Solid-State Processes in Molecular Materials	215
	<i>Adam A. L. Michalchuk, Anke Kabelitz, and Franziska Emmerling</i>	
4.8.1	In Situ Methods for Monitoring Solid-State Processes in Molecular Materials	215
4.8.1.1	The Complexity of Solid Materials	215
4.8.1.2	Methods to Consider	216
4.8.1.3	Methods to Monitor Crystallization Kinetics from Solution	218
4.8.1.3.1	UV-Vis Spectroscopy	218
4.8.1.3.2	Infrared Spectroscopy	219
4.8.1.4	Monitoring Crystallization from Solution: Following Solid Product Formation	221
4.8.1.4.1	Light Scattering	221
4.8.1.5	Methods to Monitor Extrinsic Solid Properties	224
4.8.1.5.1	Acoustic Emission	224
4.8.1.5.2	Thermography	226
4.8.1.6	Methods to Monitor Intrinsic Solid Properties	228
4.8.1.6.1	X-ray Diffraction	228
4.8.1.6.2	Raman Spectroscopy	232
4.8.1.7	Benefits of Combining Methods for In Situ Monitoring	236
4.8.1.8	Summary	240
	List of Abbreviations	242
	References	243
4.9	Application of Process Monitoring and Modeling	249
	<i>Jochen Schoell and Roberto Irizarry</i>	
4.9.1	In-process Solid Form Monitoring Techniques	249
4.9.1.1	Direct Characterization Techniques	250
4.9.1.1.1	Raman Spectroscopy	250
4.9.1.1.2	Near Infrared Spectroscopy	252
4.9.1.2	Indirect Monitoring Tools	254
4.9.1.2.1	Focused Beam Reflectance Measurement (FBRM)	254
4.9.1.2.2	Monitoring Particle Shape Using In-process Microscopy	256
4.9.1.2.3	Monitoring Solute Concentration	256
4.9.1.3	Advantages and Challenges of In Situ Solid Form Monitoring Techniques	257
4.9.2	Quantification Methods and Application to Solid Form Transformation Modeling	258
4.9.2.1	Multivariate Data Analysis	259

4.9.2.2	Data-driven Model for CLD–PSD Prediction	260
4.9.2.3	Process Modeling of Polymorph Transformation Processes	262
	List of Abbreviations	265
	References	266
4.10	Photon Density Wave (PDW) Spectroscopy for Nano- and Microparticle Sizing	271
	<i>Lena Bressel and Roland Hass</i>	
4.10.1	Classification of Particle Sizing Technologies	271
4.10.2	Particle Size and Solid Fraction Ranges	272
4.10.3	Photon Density Wave (PDW) Spectroscopy – Theory, Instrumentation, and Application Examples	275
4.10.4	Particle Sizing by PDW Spectroscopy	277
4.10.5	Sample Versus Process Measurements	280
4.10.6	Technical Implementation and Data Access	281
4.10.7	Examples for Process Analysis with PDW Spectroscopy	282
4.10.7.1	Crystallization of Lactose	283
4.10.7.2	Precipitation of Barium Sulfate	284
4.10.8	Summary	285
	List of Abbreviations	286
	References	287
5	Impact of Solid Forms on API Scale-Up	289
	<i>Sophie Janbon, Clare Mayes, and Amy L. Robertson</i>	
5.1	Introduction	289
5.2	Background	290
5.3	Small-Scale Crystallization Development	291
5.3.1	Form Selection	291
5.3.2	Solvent Selection	293
5.3.2.1	Solvent Screening	293
5.3.2.2	Solubility Diagram	294
5.3.2.3	Solubility Measurement	295
5.3.3	Crystallization Process Selection	298
5.3.3.1	Process Outline Selection	298
5.3.3.2	Process Outline Evaluation	299
5.3.3.3	Process Exploration	300
5.3.4	Process Development Conclusions	302
5.4	Crystallization Scale-Up	302
5.4.1	Crystallization Process Accommodation	303
5.4.1.1	Vessel Size and MoC	304
5.4.1.2	Agitation	304
5.4.1.3	Heat Transfer	305
5.4.1.4	Solution Addition	305
5.4.1.5	Solid Addition	305

5.4.1.6	Alternative Technologies	306
5.4.2	Risks and Common Problems	307
5.4.2.1	Metastable Forms	307
5.4.2.2	Amorphous	307
5.4.2.3	Salt Stoichiometry	308
5.4.2.4	Oiling and Phase Separations	308
5.4.3	Isolation and Drying	308
5.4.3.1	Isolation	309
5.4.3.2	Drying	311
5.4.4	Agglomeration	314
5.4.5	Particle Size Reduction	314
5.4.5.1	Delumping	314
5.4.5.2	Milling and Micronization	314
5.4.5.3	Storage and Packing	315
5.4.6	Scale-up Conclusions	315
5.5	People and Skill Requirements	315
5.6	Regulatory Requirements	315
5.6.1	Process Documentation	316
5.6.2	Safety	316
5.6.3	Quality and Manufacturability	316
5.7	Closing Remarks	317
	List of Abbreviations	318
	References	318
6	Impact on Drug Development and Drug Product Processing	325
	<i>Susanne Page and Anikó Szepes</i>	
6.1	Introduction	325
6.2	Pharmaceutical Profiling	327
6.3	Formulation Development	330
6.3.1	Liquid Formulations: Solutions and Suspensions	332
6.3.2	Solid Dosage Forms	335
6.3.3	Solubility Enhanced Formulations	339
6.3.3.1	Lipid-Based Formulations and Drug Delivery Systems	339
6.3.3.2	Solid Solutions and Amorphous Solid Dispersions	343
6.4	Process Development and Transfer to Commercial Manufacturing	344
6.4.1	Particle Size Reduction	345
6.4.2	Blending	345
6.4.3	Granulation	345
6.4.3.1	Wet Granulation and Drying	346
6.4.3.2	Dry Granulation/Roller Compaction	347
6.4.4	Tablet Compression	347
6.4.5	Film Coating	348
6.5	Control Strategy	348

6.6	Regulatory Submissions	349
	List of Abbreviations	352
	References	353
7	Workflow Management	365
	<i>Christian Große</i>	
7.1	Motivation	365
7.2	Workflow Management	365
7.3	Organization of Solid-State Development by Project Management	366
7.3.1	Stakeholders	366
7.3.2	CMC Project Management	367
7.3.3	Substance Requirement Plan	368
7.3.4	Pre-CMC Data	369
7.4	Workflows in the Environment of the Crystallization Laboratory	369
7.4.1	Micro-Project Management	369
7.4.2	Dependencies	370
7.4.3	Material Flow	371
7.4.4	Designations and Code Assignment	371
7.4.5	Analytic Database System	373
7.4.6	Physical Sample Transfer	375
7.4.7	Analytic Transfer Tool	375
7.4.8	Analytical Processes – Timely Measurement	376
7.4.9	Sample Storage Processes	377
7.4.10	Documentation	378
7.4.11	Review Process for ELN Documents	379
7.4.11.1	Document Status	379
7.4.11.2	Manual ELN Review Process	380
7.4.11.3	Archive Process	381
7.4.12	Communication with CROs	381
7.4.13	Fundamental Lab Processes	382
7.5	Processes in the Solid-State Lab	382
7.5.1	Initial Testing	382
7.5.2	Solubility Estimation	384
7.5.3	Manual Screening	384
7.5.4	High-Throughput Screening	385
7.5.5	Processes for Replica Experiments and Scale-Up of Solid Forms	387
7.6	Development of Crystallization Processes	387
7.7	Support Processes	388
7.7.1	Route Scouting Process	389
7.7.2	Crystallization of Impurities and Intermediates	389
7.7.3	Downstream Processes	389
7.7.4	Scale-Up and Technology Transfer Process	390
7.7.5	Analytical Development	390
7.7.6	Preformulation	391
7.7.7	Formulation	391

7.8	Conclusion	392
	List of Abbreviations	393
	References	393
8	Digitalization in Laboratories of the Pharmaceutical Industry	397
	<i>Tanja S. Picker</i>	
8.1	Introduction	397
8.2	Motivation of Digitalization in the Laboratory	398
8.2.1	Expectations of the Staff	398
8.2.2	Increasing Throughput	400
8.2.3	Repeatability	400
8.2.4	Enhanced Requirements on Data Integrity	400
8.2.5	Centralized Archiving	401
8.2.6	Ad Hoc Analysis	401
8.2.7	The Value of Data	402
8.3	Categories of Laboratory IT Systems	403
8.3.1	Devices	403
8.3.2	Lab Execution Systems (LES) and Scientific Data Management Systems (SDMS)	404
8.3.3	Lab Data Systems	404
8.3.4	Enterprise Resource Planning (ERP)	405
8.3.5	Further Use of Data	405
8.3.5.1	Data Analysis and Reporting	405
8.3.5.2	Big Data Analytics and Artificial Intelligence	406
8.4	System Interfaces for Data Exchange	406
8.4.1	Adapters	407
8.4.1.1	Serial Port (RS232)	407
8.4.1.2	Universal Series Bus (USB)	407
8.4.1.3	Ethernet	407
8.4.1.4	Cable Less Connections	407
8.4.2	Communication Medium and Protocols	408
8.4.2.1	File-Based Communication	408
8.4.2.2	ANSI/ISA-88 Batch Control (S-88)	408
8.4.2.3	Open Platform Communications Unified Architecture (OPC UA)	408
8.4.2.4	Standards in Lab Automation (SiLA)	408
8.4.3	Data Formats	409
8.4.3.1	Common Data Formats (e.g. TXT, XML, JSON)	409
8.4.3.2	Analytical Information Markup Language (AnIML)	409
8.4.3.3	Allotrope Data Format (ADF)	410
8.5	Implementation of IT Solutions	411
8.5.1	Identification of Digital Gaps in the Lab Processes	411
8.5.1.1	Contextual Inquiry	411
8.5.1.2	Interaction Room	411
8.5.2	Implementation Approach	412

8.5.2.1	Design	413
8.5.2.2	Realization	415
8.5.2.3	Verification	415
8.5.2.4	Rollout	416
8.6	Conclusion	416
	List of Abbreviations	416
	References	417
9.1	Polymorphs and Patents – the US Perspective	421
	<i>Kristi McIntyre</i>	
9.1.1	Introduction	421
9.1.2	What Is a Patent?	421
9.1.3	How Are Patents Obtained?	422
9.1.4	United States Patent Law	422
9.1.4.1	Tapentadol Hydrochloride	423
9.1.4.1.1	Tapentadol Hydrochloride Form A Held Not Obvious	423
9.1.4.1.2	Tapentadol Hydrochloride Form A Was Found to Have Utility	424
9.1.4.2	Paroxetine Hydrochloride Hemihydrate	424
9.1.4.2.1	PHC Hemihydrate History	425
9.1.4.2.2	Meaning of “Crystalline Paroxetine Hydrochloride Hemihydrate”	425
9.1.4.2.3	PHC Hemihydrate: Infringed, But Invalid for Anticipation	426
9.1.4.3	Ranitidine Hydrochloride	426
9.1.4.3.1	History of RHCl Form 2	426
9.1.4.3.2	RHCl Form 2 Not Anticipated by Example 32	427
9.1.4.4	Cefdinir	427
9.1.4.5	Amlodipine Besylate	428
9.1.4.5.1	History of Amlodipine Besylate	428
9.1.4.5.2	Amlodipine Besylate Found Obvious	428
9.1.4.6	Concluding Remarks	429
	Notes	429
	References	430
9.2	Polymorphs and Patents – The EU Perspective	431
	<i>Oliver Brosch</i>	
9.2.1	European Patent Applications and European Patents	431
9.2.1.1	Introduction	431
9.2.1.2	Summary of the Processing of Applications and Patents Before the European Patent Office (EPO)	431
9.2.1.3	Economic Factors	432
9.2.1.4	Unitary Patents	433
9.2.1.5	Protection of Polymorphs and Solid Forms in General	433
9.2.1.6	Polymorph Screening	434
9.2.2	Decisions of Technical Boards of Appeal of the EPO	435
9.2.2.1	Decision T 777/08 of 24 May 2011	435
9.2.2.2	Decision T 1555/12 Dated 29 April 2015	435

9.2.2.3	Decision T 2114/13 Dated 12 October 2016	442
9.2.2.4	Decision T 2397/12 Dated 12 March 2018	442
9.2.2.5	Decision T 246/15 Dated 13 November 2018	442
9.2.3	Jurisdiction of the Federal Patent Court and the German Federal Supreme Court	443
9.2.3.1	Decision “Kristallformen” German Federal Court	443
9.2.3.2	Decision X ZR 58/08 Dated 15 March 15 2011	443
9.2.3.3	Decision X ZR 98/09 Dated 15 May 2012	444
9.2.3.4	Decision X ZR 110/16 Dated 7 August 2018	444
9.2.4	Assessing Validity of a Patent or the Chances of Success	445
9.2.5	Interaction with Patent Professionals	446
	List of Abbreviations	447
	References	447

10 Regulatory Frameworks Affecting Solid-State Development

Christoph Saal

10.1	Introduction – The Need for Regulation in Pharmaceutical Industry	449
10.2	Solid-State Forms to Be Used for Drugs	451
10.3	General Regulatory Considerations for Pharmaceutical Solid-State Forms	453
10.4	Regulatory Framework for Pharmaceutical Salts	454
10.4.1	Pharmaceutical Equivalence and Pharmaceutical Alternatives	454
10.4.2	Bioequivalence	456
10.4.3	Therapeutic Equivalence	458
10.4.4	Biowaivers	458
10.4.5	Regulatory Approval for Pharmaceutical Salts	460
10.4.5.1	Regulatory Approval Pathways in the United States	460
10.4.5.2	Regulatory Approval Pathways in the European Union	461
10.4.6	Regulatory Approval for Polymorphs	463
10.4.7	Polymorphism in Pharmacopoeias	469
10.5	Regulatory Framework for Co-crystals	471
10.6	Summary	476
	List of Abbreviations	476
	References	477

11 Opportunities and Challenges for Generic Development from a Solid-state Perspective

Judith Aronhime and Mike Teiler

11.1	The Birth of a New Drug and the Generic Siblings that Will Follow – Two Different Mindsets	481
11.1.1	Generics	481
11.1.2	Proprietary Products	482
11.1.3	API and Solid State	483

11.1.3.1	Generics	483
11.1.3.2	Proprietary	483
11.2	Portfolio Management – How Is a Portfolio Constructed and Maintained?	484
11.2.1	Activities and Timelines	484
11.2.1.1	Strategy	484
11.2.1.2	Value	484
11.2.1.3	Factors Impacting on Timing – When and How Does a Product Show Up on a Generic Company’s Radar Screen?	485
11.2.2	Timing	487
11.2.2.1	When Is “On-time?”	487
11.2.3	Market-specific Considerations Based on Local Legislation and Administration (OB, PIV, Various Exclusivities – US, EU, JP, etc.)	489
11.2.3.1	Patents Through the Eyes of the Regulatory Authorities	489
11.2.3.2	Data Exclusivity (Data Protection)	489
11.2.3.3	Salts and Esters	490
11.2.3.4	Think Global, Act Local	490
11.2.4	Sources to Evaluate a Project	491
11.2.4.1	Government and Regulatory Agencies	491
11.2.4.2	Analyst Reports and Company Financial Reports	492
11.2.4.3	Pay Data Sources	492
11.2.5	Evaluation Tools	493
11.2.5.1	Business Case	493
11.2.5.2	Quality Target Project Profile (QTPP)	493
11.2.6	Criteria for Identifying Promising Projects	493
11.2.7	Criteria for Building a Robust Portfolio	494
11.3	Challenges in Developing a Generic Product from the Solid-state Perspective	495
11.3.1	Implications in Developing Formulation with a Metastable API	496
11.3.2	The Stability Question	497
11.3.2.1	Polymorphic Stability in Dry Conditions	497
11.3.2.2	Polymorphic Stability in Wet Conditions (Slurry)	498
11.4	Generic Solid-state Development	498
11.4.1	General	498
11.4.2	Predevelopment Phase: Solid-state Strategy	499
11.4.2.1	Review of the Solid State, Especially the Polymorph Patent Landscape	499
11.4.2.2	Design-around Considerations	500
11.4.3	Crystal Forms Discovery	503
11.4.3.1	Importance of the Crystal Forms Discovery Stage	503
11.4.3.2	New Crystal Forms Unpredictability	503
11.4.3.3	Pragmatic Questions About Crystal Forms Search	504
11.4.3.4	Late-appearing Polymorphs	505
11.4.3.5	Irreproducibility of Procedures	506
11.4.3.6	Analytical Focus	507

11.4.4	Target Selection	507
11.4.4.1	Solubility	508
11.4.4.2	Morphology	509
11.4.4.3	Solid-state Stability	509
11.4.4.4	Additional Factors	509
11.4.5	Process Development in the Laboratory Scale	510
11.4.5.1	Process Development	510
11.4.5.2	Thermodynamic Stability Relationships	510
11.4.5.3	Solubility Curves	510
11.4.5.4	API Target	511
11.4.5.5	Analytical Methods for Polymorphic Purity	512
11.4.6	Scale-up Challenges	512
11.4.6.1	Control of Crystal Form	512
11.4.6.2	Control of Particle Size and Morphology	513
11.4.6.3	Lot-to-Lot Variability	513
11.4.6.4	Analytical Focus	514
11.4.7	Pharma Development	515
11.4.7.1	The Tetrahedron Principle and Consistency Among Lots	516
11.4.7.2	The Effect of Micronization on Amorphous Content in Crystalline APIs	516
11.4.7.3	Solid-state Stability upon Storage	517
11.4.8	Impact on Formulation	517
11.4.9	Summary of Timelines for Solid-state Activity	518
11.4.10	Intellectual Property (IP) Strategies and Activities	519
11.5	Success Factors	520
11.5.1	Successful Biostudy	520
11.5.2	Successful Launch	521
11.5.3	Generic Commercial Success	522
	List of Abbreviations	523
	References	524

Index	531
--------------	------------